GlassScriptPhysician profile
Megha Shah
NPI 1437393352
$16,787.50
in general payments reported to CMS, 2019-2025
78 companies · $4,220 in 2025
The $4,220 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $406 · 2021: $479 · 2022: $767 · 2023: $4,052 · 2024: $6,071 · 2025: $4,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,270 · Food and Beverage: $4,004 · Long Term Medical Supply Or Device Loan: $997 · Education: $71.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,270.00 |
| Food and Beverage | $4,004.25 |
| Long Term Medical Supply Or Device Loan | $997.00 |
| Education | $71.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $3,191.27 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Astrazeneca Pharmaceuticals LP | $2,947.37 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Alnylam Pharmaceuticals INC. | $2,300.00 | 2024 | Givlaari |
| Novartis Pharmaceuticals Corporation | $1,392.94 | 2019-2025 | |
| Mirati Therapeutics, INC. | $882.17 | 2023 | Krazati |
| Astellas Pharma US INC | $786.64 | 2019-2024 | Xtandi, Padcev |
| Janssen Biotech, INC. | $522.41 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Genzyme Corporation | $264.32 | 2019-2025 | |
| Pfizer INC. | $233.12 | 2019-2025 | |
| Gilead Sciences, INC. | $226.42 | 2019-2025 | Trodelvy |
| Stemline Therapeutics INC. | $226.27 | 2023-2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $219.13 | 2020-2025 | Opdivo, Opdualag, Krazati |
| Abbvie INC. | $189.63 | 2021-2025 | Venclexta |
| Seagen INC. | $186.08 | 2019-2023 | Tukysa |
| Regeneron Healthcare Solutions, INC. | $175.34 | 2019-2025 | Libtayo |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $168.69 | 2023-2024 | Vegzelma |
| Celgene Corporation | $159.77 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Incyte Corporation | $152.75 | 2019-2025 | Pemazyre, Monjuvi, Jakafi |
| Lilly USA, LLC | $144.76 | 2019-2024 | Verzenio, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $142.12 | 2019-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Glaxosmithkline, LLC. | $134.88 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Amgen INC. | $123.05 | 2019-2023 | Blincyto, Kyprolis, Lumakras |
| Eisai INC. | $113.19 | 2019-2024 | |
| Beigene USA, INC. | $109.97 | 2023-2025 | Brukinsa, Tevimbra |
| Genentech USA, INC. | $97.94 | 2019-2024 | Venclexta |
| Aveo Pharmaceuticals, INC. | $73.80 | 2021-2024 | Fotivda |
| Springworks Therapeutics, INC. | $67.18 | 2024-2025 | Ogsiveo, Gomekli |
| Taiho Oncology, INC. | $64.36 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $64.08 | 2019-2023 | Imbruvica, Epkinly |
| Ipsen Biopharmaceuticals, INC | $61.13 | 2019-2025 | Onivyde, Somatuline Depot |
| Ge Healthcare | $57.46 | 2022 | |
| Foundation Medicine, INC. | $57.45 | 2022-2023 | |
| Array Biopharma INC | $56.21 | 2023-2024 | Braftovi, Lorbrena, Mektovi |
| Servier Pharmaceuticals LLC | $54.38 | 2021-2024 | |
| Sobi, INC | $52.78 | 2025 | |
| Karyopharm Therapeutics INC. | $50.09 | 2023-2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $49.83 | 2019-2024 | Ultomiris |
| Exelixis INC. | $49.05 | 2019-2023 | Cabometyx |
| Janssen Pharmaceuticals, INC | $45.82 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $45.51 | 2020-2023 | |
| Adaptive Biotechnologies Corporation | $44.59 | 2023-2025 | Clonoseq |
| Apellis Pharmaceuticals, INC. | $44.14 | 2021-2023 | Empaveli |
| Puma Biotechnology, INC. | $43.93 | 2020-2023 | Nerlynx |
| Fresenius Kabi USA, LLC | $42.89 | 2023-2024 | Stimufend |
| Myovant Sciences INC. | $42.63 | 2021-2022 | |
| Coherus Oncology, INC. | $39.75 | 2021 | |
| Genmab U.S., INC. | $38.68 | 2023-2024 | Epkinly |
| Geron Corporation | $33.80 | 2025 | Rytelo |
| Morphosys, US INC. | $33.36 | 2021-2023 | Monjuvi |
| Emd Serono, INC. | $31.59 | 2023-2024 | Bavencio |
| Kyowa Kirin, INC. | $31.46 | 2019-2024 | Poteligeo |
| Blueprint Medicines Corporation | $29.59 | 2022-2023 | Ayvakit |
| Tempus Ai, INC | $29.17 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.69 | 2019-2021 | |
| Heron Therapeutics, INC. | $24.10 | 2023 | Sustol |
| Menarini Silicon Biosystems, INC. | $20.94 | 2025 | Cellsearch |
| Agios Pharmaceuticals, INC. | $20.79 | 2025 | Pyrukynd |
| Azurity Pharmaceuticals, INC. | $19.07 | 2025 | Vivimusta, Danziten |
| Fennec Pharmaceuticals, INC. | $18.65 | 2025 | Fyarro |
| Beone Medicines USA, INC. | $17.22 | 2025 | Brukinsa |
| Syndax Pharmaceuticals, INC. | $16.85 | 2025 | Niktimvo |
| Ferring Pharmaceuticals INC. | $16.70 | 2023 | Rebyota |
| Cumberland Pharmaceuticals, INC. | $15.42 | 2024 | Sancuso |
| Merck Sharp & Dohme LLC | $14.99 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.68 | 2025 | Alymsys |
| Helsinn Therapeutics (U.S.), INC. | $14.64 | 2019 | |
| Rigel Pharmaceuticals, INC. | $14.45 | 2022 | |
| Tersera Therapeutics LLC | $14.27 | 2019 | |
| Organon LLC | $13.37 | 2021 | |
| Dova Pharmaceuticals | $12.79 | 2019 | |
| Octapharma USA, INC. | $12.29 | 2022 | |
| Kite Pharma, INC. | $12.08 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.07 | 2019 | |
| Epizyme, INC. | $12.06 | 2022 | |
| Fortovia Therapeutics, INC. | $9.91 | 2019 | |
| Secura Bio, INC. | $9.53 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megha Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.